Literature DB >> 21220013

Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation.

M Sta1, R M R Sylva-Steenland, M Casula, J M B V de Jong, D Troost, E Aronica, F Baas.   

Abstract

Increasing evidence suggests a role for the immune system in amyotrophic lateral sclerosis (ALS). To determine the extent of the immune activation in ALS we analyzed the expression and cellular distribution of components of innate and adaptive immunity in spinal cord (SC) and motor cortex (MCx) from patients with rapid and slow sporadic ALS and controls. High levels of mRNA and protein of classical complement pathway, C1q and C4, as well as the downstream complement components C3 and C5b-9 were found in all ALS samples. Furthermore, we found higher numbers of activated microglia, reactive astrocytes, dendritic cells (DCs) and CD8(+) T-cells in ALS than in control tissue. Rapid ALS cases had more dendritic cells than slow ALS cases, whereas slow ALS cases had more activated microglia than rapid cases. Our findings demonstrate a persistent and prominent activation of both innate and adaptive immunity in ALS. We propose a complement-driven immune response which may contribute to the progression of the inflammation and ultimately lead to even more motor neuron injury.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220013     DOI: 10.1016/j.nbd.2011.01.002

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  57 in total

Review 1.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

2.  C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice.

Authors:  Christian S Lobsiger; Severine Boillée; Christine Pozniak; Amir M Khan; Melissa McAlonis-Downes; Joseph W Lewcock; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

Review 3.  Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders.

Authors:  Vera Paschon; Silvia Honda Takada; Juliane Midori Ikebara; Erica Sousa; Reza Raeisossadati; Henning Ulrich; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.590

Review 4.  Use of biomarkers in ALS drug development and clinical trials.

Authors:  Nadine Bakkar; Ashley Boehringer; Robert Bowser
Journal:  Brain Res       Date:  2014-10-24       Impact factor: 3.252

Review 5.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

Review 6.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

Review 7.  Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.

Authors:  Laura Ferraiuolo; Janine Kirby; Andrew J Grierson; Michael Sendtner; Pamela J Shaw
Journal:  Nat Rev Neurol       Date:  2011-11       Impact factor: 42.937

Review 8.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

9.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

Review 10.  Inflammation in neurodegenerative diseases--an update.

Authors:  Sandra Amor; Laura A N Peferoen; Daphne Y S Vogel; Marjolein Breur; Paul van der Valk; David Baker; Johannes M van Noort
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.